drugset / Trial / NCT06284486
A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib
Phase 1/2
Recruiting
8 enrolled
M.D. Anderson Cancer Center
AbbVie · collabSyndax Pharmaceuticals · collab
NaSingle-groupOpen-labelTreatment
Summary
To learn if the combination of venetoclax and revumenib can help to control MRD-positive AML.
Timeline
- Start
- 2024-09-23
- Primary completion
- 2026-12-30
- Completion
- 2028-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Revumenib | Small molecule | — | Oral |
| Subject | Venetoclax | Small molecule | — | Oral |